JUN 27, 2017 08:00 AM PDT

WEBINAR: Investigating the Genetics of Human Macrophage Response and Resistance to Mycobacterium tuberculosis with AmpliSeq™ Gene Expression Panels

  • Technical Director, The Ohio State University
      Audrey Papp is a Research Specialist and Technical Director of the Pharmacogenomics Core Laboratory at the Ohio State University College of Medicine Center for Pharmacogenomics. As technical director, Audrey played a leading role in implementation of Next Generation Sequencing in the Pharmacogenomics (PGx) Core Laboratory. The PGx Core Lab is currently using Ion Torrent PGM, and Ion Proton deep sequencing platforms. Under Audrey's guidance, the OSU Pharmacogenomics Core Lab was designated as an Ion Torrent Certified Service Provider, recognized for proficiency in Exome, RNA transcriptome and AmpliSeq transcriptome sequencing as well as other molecular techniques. Audrey's expertise continues to be instrumental in developing new methods and approaches geared towards discovery of functional genetic biomarkers.

      In her career, Audrey has been successful at design and implementation of new concepts and programs in both research and clinical areas. Previously, as supervisor of the Clinical Molecular Pathology Laboratory in the Department of Pathology at The Ohio State University Medical Center, she played a key role in developing the test portfolio, and establishing the Molecular Pathology Laboratory as a CLIA certified lab. In addition to participation in both clinical and research aspects of health care, she is a contributing author on over 80 papers. Audrey has been a featured speaker, and workshop leader at national conferences, webcasts and other events. One of her most recent projects was to create a new OSU graduate course: Personalized Therapeutics and Pharmacogenomics, a 3 credit online class in the new OSU Master's Program in Translational Pharmacology. Audrey is currently working on a pilot project with the Bill and Melinda Gates Foundation to develop better tuberculosis vaccines using targeted transcriptome sequencing and functional genetic variant analysis.


    DATE: June 27, 2017
    TIME: 8:00am PT, 11:00am ET

    The purpose of this study is to identify genetic variants that influence cellular responses, and patterns of M.tb infection and growth in human alveolar macrophages.

    We used next-generation RNA sequencing, and DNA genotyping to identify candidate genes and gene networks, reveal operative genetic variants and address genotype-RNA-cellular phenotype relationships in M.tb-infected human alveolar macrophage cultures on a genome-wide scale. The Ion AmpliSeq transcriptome assay enables highly sensitive and reproducible measurement of differential gene expression, facilitating downstream enables highly sensitive and reproducible measurement of differential gene expression, facilitating downstream network and component analysis. We follow up with custom designed AmpliSeq allelic expression assays on a selection of high priority genes, to quantitatively measure effects on expression, and characterize causal variants in individual donors. We then test the health related effects of these functional variants in existing human genome wide association studies of tuberculosis related phenotypes. Our overarching goal is to use this specific genetic and phenotypic information to guide tuberculosis vaccine development, and to better predict individual response.

    • How to improve biomarker discovery using NGS
    • Benefits of applying a targeted gene-expression based approach for studying genotype-RNA-cellular phenotype relationships
    • How to implement the Ion AmpliSeq Human Transcriptome Gene Expression assay to guide vaccine development and predict individual response.

    For Research Only. Not for use in diagnostic procedures.

    Show Resources